Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1257
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Etodolac (Tablet)
|
| dailymed-instance:dosage |
As with other NSAIDs, the lowest dose and longest dosing interval should be sought for each patient. Therefore, after observing the response to initial therapy with etodolac, the dose and frequency should be adjusted to suit an individual patient's needs. Dosage adjustment of etodolac is generally not required in patients with mild to moderate renal impairment. Etodolac should be used with caution in such patients, because, as with other NSAIDs, it may further decrease renal function in some patients with impaired renal function. .<br/>Analgesia: The recommended total daily dose of etodolac for acute pain is up to 1000 mg, given as 200-400 mg every 6 to 8 hours. In some patients, if the potential benefits outweigh the risks; the dose may be increased to 1200 mg/day in order to achieve a therapeutic benefit that might not have been achieved with 1000 mg/day. Doses of etodolac greater than 1000 mg/day have not been adequately evaluated in well-controlled clinical trials.<br/>Osteoarthritis: The recommended starting dose of etodolac for the management of the signs and symptoms of osteoarthritis is: 300 mg b.i.d., t.i.d., or 400 mg b.i.d., or 500 mg b.i.d. During long-term administration, the dose of etodolac may be adjusted up or down depending on the clinical response of the patient. A lower dose of 600 mg/day may suffice for long-term administration. In patients who tolerate 100 mg/day, the dose may be increased to 1200 mg/day when a higher level of therapeutic activity is required. When treating patients with higher doses, the physician should observe sufficient increased clinical benefit to justify the higher dose. Physicians should be aware that doses above 1000 mg/day have not been adequately evaluated in well-controlled clinical trials. In chronic conditions, a therapeutic response to therapy with etodolac is sometimes seen within one week of therapy, but most often is observed by two weeks. After a satisfactory response has been achieved, the patient's dose should be reviewed and adjusted as required.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:hydroxypropyl_methylcellulose,
dailymed-ingredient:lactose_monohydrate,
dailymed-ingredient:magnesium_stearate,
dailymed-ingredient:microcrystalline_cellulose,
dailymed-ingredient:polyethylene_glycol,
dailymed-ingredient:polysorbate_80,
dailymed-ingredient:povidone,
dailymed-ingredient:red_iron_oxide,
dailymed-ingredient:sodium_starch_glycolate,
dailymed-ingredient:titanium_dioxide,
dailymed-ingredient:yellow_iron_oxide
|
| dailymed-instance:possibleD... | |
| dailymed-instance:genericMe... |
Etodolac
|
| dailymed-instance:fullName |
Etodolac (Tablet)
|
| dailymed-instance:indicatio... |
Etodolac is indicated for acute and long-term use in the management of signs and symptoms of osteoarthritis. Etodolac is also indicated for the management of pain.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Etodolac
|